Keyphrases
Visceral Leishmaniasis
100%
Human African Trypanosomiasis
47%
Drug Target
47%
Trypanosoma Cruzi (T. cruzi)
42%
Chagas Disease
40%
Preclinical Candidate
35%
Mouse Model
34%
Cyclin-dependent Kinase 12
27%
Diaminothiazoles
27%
N-Myristoyltransferase Inhibitors
27%
Protease Inhibitors
27%
Mode of Action
24%
In Vivo Efficacy
24%
Trypanosoma Brucei
23%
Central Nervous System
20%
Compound 8
20%
Current Treatment
19%
Proteasome Inhibition
18%
Leishmania Donovani
17%
Metabolic Stability
16%
Parasitic Infection
15%
New Drugs
15%
Protozoan Parasites
14%
Mycobacterium Tuberculosis (M. tb)
14%
Inhibitor Identification
13%
Pyrazolo
13%
Pyrimidine
13%
Naphthyridine
13%
Antileishmanial Activity
13%
In Vivo Activity
13%
Preclinical Development
13%
Disubstituted piperazines
13%
1,2,3-Triazole-4-carboxamide
13%
Publication Process
13%
Material Difference
13%
Amino
13%
Guided Synthesis
13%
Potential Treatments
13%
Pyridazinone
13%
Malaria
13%
Penetrant
13%
Cyclin-dependent Kinase
13%
Inhibitor Evaluation
13%
Brain Penetrant
13%
Molecular Hybridization
13%
Pyrazole Sulfonamides
13%
Medicinal Chemistry
13%
Cryptosporidiosis
13%
Infectious Diseases
13%
Drug Development
13%
Pharmacology, Toxicology and Pharmaceutical Science
Visceral Leishmaniasis
100%
Trypanosoma Cruzi
42%
Chagas Disease
40%
Cyclin Dependent Kinase
40%
Mouse Model
38%
Proteasome
31%
African Trypanosomiasis
31%
Infection
31%
Diseases
30%
Pharmacokinetics
27%
Proteasome Inhibitor
27%
Structure Activity Relationship
20%
Hexachlorophene
17%
Trypanosoma Brucei
16%
Parasitosis
15%
Protozoon
14%
Naphthyridine Derivative
13%
Piperazine Derivative
13%
Sulfonamide
13%
Lysine Transfer RNA Ligase
13%
Amitrole
13%
Pyrimidine Derivative
13%
Pyrazole
13%
Pharmaceutical Chemistry
13%
Drug Development
13%
Carboxamide
13%
Nagana
13%
Cryptosporidiosis
13%
Drug Discovery
13%
Drug Metabolism
13%
Mycobacterium avium
13%
Mycobacterium abscessus
13%
Dihydrofolate Reductase Inhibitor
13%
Cryo-Electron Microscopy
12%
Dihydrofolate Reductase
10%
Atypical Mycobacterium
10%
Wild Type Mouse
9%
Apicomplexa
8%
Leishmania donovani
7%
Molecular Target
7%
Tolerability
6%
Divalent
6%
Piperazine
6%
Neglected Disease
6%
High-Content Screening
6%
Side Effect
6%
Benznidazole
6%
Nifurtimox
6%
Metal Ion
6%
Leishmania infantum
6%